```html

XDR Tuberculosis (Extensively Drug‑Resistant TB) – Comprehensive Guide

Overview

Extensively drug‑resistant tuberculosis (XDR‑TB) is a form of pulmonary (or sometimes extrapulmonary) tuberculosis that is resistant not only to the two most powerful first‑line anti‑TB drugs—isoniazid and rifampicin—but also to any fluoroquinolone and at least one of the three injectable second‑line drugs (amikacin, capreomycin, or kanamycin). Because it is resistant to most available medicines, XDR‑TB is harder to treat, requires longer therapy, and carries a higher risk of death.

• Who it affects: Anyone can acquire XDR‑TB, but the disease is most common among people who have previously been treated for TB, individuals living with HIV, and those in settings with weak infection‑control practices (e.g., crowded prisons, refugee camps, or poorly ventilated health facilities).
• Global prevalence: According to the World Health Organization (WHO) 2023 Global TB Report, there were an estimated ≈ 9,000 cases of XDR‑TB reported worldwide in 2022, representing 0.8 % of all TB cases and 6 % of multidrug‑resistant TB (MDR‑TB) cases.<sup>1</sup> The highest burdens are in India, the Russian Federation, South Africa, and the Philippines.
• Mortality: The case‑fatality rate for XDR‑TB can exceed 50 % in patients with HIV co‑infection and is roughly 20–30 % higher than for MDR‑TB when appropriate individualized regimens are not used.<sup>2</sup>

Symptoms

The clinical picture of XDR‑TB mirrors that of drug‑susceptible TB, but symptoms may persist or worsen despite standard therapy.

• Persistent cough (≥2 weeks): Often productive, sometimes with blood‑tinged sputum (hemoptysis).
• Fever: Low‑grade to high‑grade, often worse in the evenings.
• Night sweats: Profuse sweating that soaks clothing or bedding.
• Weight loss & loss of appetite: “Wasting” is common, especially in HIV‑positive patients.
• Chest pain: May be pleuritic or due to cavitary lesions.
• Fatigue & malaise: Generalized weakness that interferes with daily activities.
• Shortness of breath: When extensive lung involvement or pleural effusion occurs.
• Extrapulmonary manifestations (≈15 % of XDR‑TB cases): Lymphadenitis, meningitis, spinal (Pott’s disease), pericarditis, or disseminated (miliary) TB, especially in immunocompromised hosts.

When symptoms continue or recur after 2–3 months of standard TB therapy, clinicians should suspect drug resistance and order appropriate testing.

Causes and Risk Factors

Underlying cause

XDR‑TB results from infection with Mycobacterium tuberculosis strains that have acquired mutations conferring resistance to multiple drug classes. Resistance develops through:

• Inappropriate or incomplete treatment: Missed doses, early discontinuation, or irregular drug supply.
• Transmission of already resistant strains: Direct person‑to‑person spread, especially in crowded, poorly ventilated environments.
• Pharmacokinetic issues: Malabsorption (e.g., in HIV, diabetes), drug–drug interactions, or sub‑therapeutic dosing due to poor weight‑based calculations.

Risk factors

• History of prior TB treatment (especially with irregular adherence).
• Living with HIV/AIDS or other conditions that weaken immunity.
• Close contact with known MDR‑TB or XDR‑TB patients.
• Residence in high‑burden settings (prisons, shelters, refugee camps).
• Diabetes mellitus, chronic lung disease, or malnutrition.
• Suboptimal infection‑control practices in health‑care facilities.
• Use of second‑line drugs without proper drug‑susceptibility testing.

Diagnosis

Accurate and timely diagnosis is essential because delayed identification increases transmission and worsens outcomes.

Clinical evaluation

• Detailed history (symptom duration, previous TB treatment, HIV status, exposure history).
• Physical exam focusing on respiratory findings, lymphadenopathy, and neurological deficits.

Microbiologic tests

1. Sputum smear microscopy: Rapid (within hours) but cannot detect drug resistance.
2. Culture (solid or liquid media): Gold standard for confirming TB; takes 2–6 weeks.
3. Rapid molecular assays:
   • GeneXpert MTB/RIF Ultra – detects M. tuberculosis DNA and rifampicin resistance in < 2 hours.
   • Line‑probe assays (e.g., Hain MTBDRplus/sl) – detect mutations conferring resistance to isoniazid, rifampicin, fluoroquinolones, and injectable agents.
4. Whole‑genome sequencing (WGS): Increasingly used in reference labs to map the full resistance profile.

Additional investigations

• Chest radiography: Cavitary lesions, infiltrates, or fibrosis.
• CT scan: Provides detailed view of cavitation, mediastinal nodes, or extrapulmonary disease.
• HIV testing: Recommended for all TB patients.
• Baseline labs: CBC, liver function, kidney function, electrolytes (important for drug monitoring).

Treatment Options

Because XDR‑TB is resistant to most first‑ and second‑line drugs, therapy must be individualized based on drug‑susceptibility testing (DST) and patient tolerance. The WHO recommends a 6‑month intensive phase followed by a 12‑month continuation phase, using at least five effective drugs.

Core drug groups

1. Group A (recommended):
   • Levofloxacin or moxifloxacin (if susceptibility remains).
   • Bedaquiline (Bdq) – novel diarylquinoline, oral, 6 months.
   • Linezolid (Lzd) – oxazolidinone, 6–12 months.
2. Group B (add if needed):
   • Cycloserine or terizidone.
   • Clofazimine (Cfz).
3. Group C (reserve):
   • Delamanid (Dlm) – another diarylquinoline.
   • Ethionamide/prothionamide.
   • Amikacin, streptomycin, or other injectables (only if necessary, due to toxicity).

Adjunctive measures

• Surgical resection: Considered for localized disease with massive hemoptysis or persistent cavities after drug therapy.
• Therapeutic drug monitoring (TDM): Ensures adequate plasma concentrations, especially for linezolid and bedaquiline.
• Management of comorbidities: Antiretroviral therapy for HIV, glycemic control for diabetes.
• Supportive care: Nutritional supplementation, correction of anemia, and psychosocial support.

Side‑effects & monitoring

Drug	Common adverse effect	Monitoring
Bedaquiline	QT prolongation, hepatotoxicity	ECG baseline & monthly, LFTs
Linezolid	Peripheral neuropathy, myelosuppression	CBC weekly, neuropathy assessment
Cycloserine	Psychiatric symptoms (depression, psychosis)	Mental‑status screening
Fluoroquinolones	Tendinopathy, QT prolongation	Joint exam, ECG if risk factors
Injectables	Nephro‑ and ototoxicity	Renal function, audiometry

Duration

Typical total treatment length is 18 months, but may be shortened to 12 months if rapid sputum conversion (<2 months) is achieved and the regimen contains ≥3 new drugs with confirmed activity.<sup>3</sup>

Living with XDR Tuberculosis (Extensively Drug‑Resistant TB)

Managing XDR‑TB goes beyond medication; it involves daily habits that improve outcomes and protect others.

Adherence strategies

• Enroll in a directly observed therapy (DOT) program or use video‑DOT (smartphone‑based).
• Set daily medication alarms; keep a pill organiser.
• Coordinate with a case manager or community health worker.

Nutrition & hydration

• Consume a balanced diet rich in protein, vitamins A, C, D, and zinc to support immune function.
• Aim for 2 – 2.5 L of fluids daily unless contraindicated.
• Consider supplementation (e.g., multivitamins, iron) after labs confirm deficiency.

Infection control at home

• Sleep in a well‑ventilated room; keep windows open when weather permits.
• Avoid crowded indoor spaces until sputum conversion is documented.
• Use a surgical mask when coughing; dispose of tissues safely.
• Regularly clean surfaces with disinfectant (e.g., bleach solution).

Managing side effects

• Report peripheral neuropathy early; dose adjustment of linezolid may be needed.
• For hearing loss from injectables, request audiometry; consider switching to oral agents.
• Psychiatric support for cycloserine‑related mood changes.

Psychosocial support

• Join support groups (online or local) for TB patients.
• Seek counseling if experiencing depression or anxiety.
• Maintain communication with family and employers about necessary accommodations.

Prevention

• Prompt diagnosis and complete treatment of drug‑susceptible TB: Prevents evolution to MDR/XDR forms.
• Infection‑control measures in health‑care settings: Negative‑pressure rooms, UV germicidal irradiation, and strict mask policies.
• Vaccination: Bacillus Calmette‑Guérin (BCG) offers limited protection against severe pediatric TB; research on new vaccines is ongoing.
• Contact tracing and chemoprophylaxis: Treat close contacts with appropriate preventive therapy (e.g., levofloxacin‑based regimens if resistant).
• Public health strategies: Strengthen drug‑supply chains, ensure rapid molecular testing availability, and improve patient education.

Complications

If XDR‑TB remains untreated or inadequately treated, the following complications may develop:

• Progressive pulmonary destruction: Cavities, fibrosis, and bronchiectasis leading to chronic respiratory failure.
• Hemoptysis: Massive bleeding from eroded bronchial arteries.
• Extrapulmonary spread: Meningitis, pericarditis, spinal (vertebral) disease, or disseminated miliary TB.
• Drug toxicity: Renal failure, irreversible hearing loss, severe QT prolongation, or bone‑marrow suppression.
• Secondary infections: Super‑infection with bacterial pneumonia or opportunistic fungi.
• Psychosocial consequences: Stigma, loss of employment, and mental health disorders.

When to Seek Emergency Care

---

Sources:
1. World Health Organization. Global Tuberculosis Report 2023. doi:10.2471/BLT.22.287840.
2. G. Dheda et al. “Extensively drug‑resistant tuberculosis,” The Lancet Respiratory Medicine, 2022.
3. WHO Consolidated Guidelines on Drug‑Resistant TB Treatment, 2022. doi:10.2471/BLT.22.287840.
Additional clinical details adapted from Mayo Clinic, CDC, and NIH Tuberculosis Guidelines. ```